Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity

PHASE3CompletedINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

October 30, 2019

Primary Completion Date

August 18, 2022

Study Completion Date

August 18, 2022

Conditions
Retinopathy of Prematurity
Interventions
DRUG

aflibercept

Administered IVT

PROCEDURE

laser photocoagulation

Transpupillary conventional laser will be administered according to standard local procedures.

Trial Locations (52)

1407

Regeneron Study Site, Sofia

1504

Regeneron Study Site, Sofia

4522

Regeneron Study Site, Adana

9002

Regeneron Study Site, Varna

10017

Regeneron Study Site, New York

10029

Regeneron Study Site, New York

10330

Regeneron Study Site, Pathum Wan

10400

Regeneron Study Site, Ratchathewi

10462

Regeneron Study Site, The Bronx

10595

Regeneron Study Site, Valhalla

11203

Regeneron Study Site, Brooklyn

11213

Regeneron Study Site, Brooklyn

14209

Regeneron Study Site, Buffalo

26480

Regeneron Study Site, Eskişehir

26506

Regeneron Study Site, Morgantown

31151

Regeneron Study Site, Cheonan

32608

Regeneron Study Site, Gainesville

40002

Regeneron Study Site, Khon Kaen

44106

Regeneron Study Site, Cleveland

48073

Regeneron Study Site, Royal Oak

48105

Regeneron Study Site, Ann Arbor

50034

Regeneron Study Site, Medellín

50200

Regeneron Study Site, Chiang Mai

60612

Regeneron Study Site, Chicago

70000

Regeneron Study Site, Ho Chi Minh City

73104

Regeneron Study Site, Oklahoma City

78229

Regeneron Study Site, San Antonio

78240

Regeneron Study Site, San Antonio

78705

Regeneron Study Site, Augusta

Regeneron Study Site, Austin

81346

Regeneron Study Site, Kaohsiung City

85016

Regeneron Study Site, Phoenix

90110

Regeneron Study Site, Hat Yai

92093

Regeneron Study Site, La Jolla

92123

Regeneron Study Site, San Diego

92354

Regeneron Study Site, Loma Linda

92868

Regeneron Study Site, Orange

94143

Regeneron Study Site, San Francisco

94303

Regeneron Study Site, Palo Alto

100000

Regeneron Study Site, Huế

119571

Regeneron Study Site, Moscow

119620

Regeneron Study Site, Moscow

194100

Regeneron Study Site, Saint Petersburg

681004

Regeneron Study Site, Floridablanca

700038

Regeneron Study Site, Iași

02111

Regeneron Study Site, Boston

02905

Regeneron Study Site, Providence

708 52

Regeneron Study Site, Ostrava-Poruba

H-4032

Regeneron Study Site, Debrecen

833 40

Regeneron Study Site, Bratislava

06100

Regeneron Study Site, Ankara

06560

Regeneron Study Site, Ankara

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY

NCT04101721 - Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity | Biotech Hunter | Biotech Hunter